Lifitegrast, a novel drug for the treatment of dry eye disease
YAO Jie
Abstract：Lifitegrast is a novel small T-cell inhibitor,which targets the inflammatory pathways involved in the dry eye disease (DED) by blocking the binding of intercellular adhesion molecule (ICAM-1) to the integrin lymphocyte function-associated antigen 1 (LFA-1) and inhibiting T cell-mediated inflammation associated with DED.Lifitegrast is a prospective drug for the treatment of DED,demonstrating a dose-dependent response in the relieving of both signs and symptoms.In Vitro assays and in vivo studies showed that lifitegrast is well tolerated and has mild side effects.Lifitegrast has been approved by FDA in July 2016.We summarized its pharmacological effect,pharmacokinetics,clinical use and safety in this article.
Keywords：dry eye diseaseocular inflammationT-cell inhibitorhigh affinityhigh specificitylifitegrast
Publication Date：2017-01-01
Online Publishing Date：2026-08-14(First online date of this platform, not the publication date of the document)
Pages：4( 1249-1252 )